Dr. George Alexandrakis, MD

Dr. Alexandrakis practices at George Alexandrakis, MD in Bakersfield, California.

Dr. Alexandrakis' NPI, 1922167501, was assigned on December 8, 2006. Dr. Alexandrakis graduated from The Robert Larner, M.D. College of Medicine in 1996. Dr. Alexandrakis holds California license A74492.

Dr. Alexandrakis' primary practice is George Alexandrakis, MD, at 1851 Oak St, Bakersfield, CA 93301-3003. The practice phone is (661) 323-4200.

Dr. Alexandrakis' primary practice is George Alexandrakis, MD in Bakersfield, California.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alexandrakis practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Alexandrakis' primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Alexandrakis is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Alexandrakis' licenses on file in 4 states: California, Idaho, Florida and South Carolina.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eyelid inflammation, glaucoma and glaucoma surgery among the conditions Dr. Alexandrakis treats.

CMS data shows 9,358 Medicare services from Dr. Alexandrakis across 15 procedure codes in 2024, for 974 Medicare patients. Medicare paid $637,418 for them.

CMS counts 974 Medicare patients who saw Dr. Alexandrakis in 2024. The largest group is 65 to 74, with 440 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 73% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alexandrakis' median patient age at 68, with 58% women.

In 2024, Dr. Alexandrakis wrote 6,388 Medicare Part D claims for 1,053 patients. 63% of them were for generic drugs. CMS names the drug for 6,323 of them, across 20 drugs with 11 or more claims each, at $322,383 in total drug cost. In 2023, CMS named 5,077 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Alexandrakis for performance year 2024, reported individually. Dr. Alexandrakis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 254 procedures of cataract surgery by Dr. Alexandrakis, more than 87% of the clinicians it reports for that procedure.

Dmand AI links 28 papers to Dr. Alexandrakis in 2009. The most frequent topics are Visual Acuity, Vitrectomy and Cataract Extraction. Dr. Alexandrakis has published most often in Am J Ophthalmol. Dr. Alexandrakis' most frequent co-authors are Harry W. Flynn, MD, Timothy G. Murray, MBA, MD and Eduardo Alfonso, MD.

CMS Open Payments shows 20 general payments to Dr. Alexandrakis from 4 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $251.

Dmand AI lists 5 awards for Dr. Alexandrakis, most recently Fight for Sight Fellowship in 1994.

Dr. Alexandrakis graduated from The Robert Larner, M.D. College of Medicine in 1996.

Dr. Alexandrakis is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.